TNFRSF18 and neoplasm: Therapeutic antibodies targeting GITR have shown therapeutic efficacy in preclinical tumor models, characterized by reduced and functionally altered intra-tumoral Tregs and enhanced anti-tumor CD8+T cell function (123).